---
_schema: default
id: 2265
date: 2024-11-21
title: >-
    What characterizes the chronic phase of CML?
article_title: >-
    What characterizes the chronic phase of CML?
date_format: MMM DD, YYYY
post_on_text: Posted on
seo:
  title: QuickTakes | Medicine
  page_description: >-
    The chronic phase of Chronic Myeloid Leukemia (CML) is characterized by stable blood cell composition, manageable symptoms, a favorable prognosis, effective treatment with tyrosine kinase inhibitors, and the need for regular clinical monitoring.
  page_keywords: >-
    CML, Chronic Myeloid Leukemia, chronic phase, white blood cells, blasts, symptoms, fatigue, splenomegaly, prognosis, tyrosine kinase inhibitors, treatment options, clinical monitoring
author: QuickTakes
question: >-
    What characterizes the chronic phase of CML?
answer: >-
    The chronic phase of Chronic Myeloid Leukemia (CML) is characterized by a relatively stable and manageable condition compared to the later phases of the disease. Here are the key features of the chronic phase:\n\n1. **Cell Composition**: In the chronic phase, immature white blood cells, known as blasts, typically make up about 10% of the cells in the blood and bone marrow. This is in contrast to the accelerated phase, where blasts constitute 10% to 19% of the cells.\n\n2. **Symptoms**: Many patients in the chronic phase may be asymptomatic or experience mild symptoms. Common symptoms can include fatigue, night sweats, unexplained weight loss, and a feeling of fullness or pain below the ribs due to splenomegaly (enlarged spleen). However, some individuals may not exhibit any noticeable symptoms at this stage.\n\n3. **Prognosis**: The chronic phase is generally associated with a better prognosis and is the easiest phase to treat. Approximately 80% to 90% of individuals diagnosed with CML present in this phase, which allows for effective management and treatment options.\n\n4. **Treatment Options**: The chronic phase is typically treated with tyrosine kinase inhibitors (TKIs), which have significantly improved the outlook for patients. The response to treatment is often favorable, and many patients can achieve a treatment-free remission after prolonged use of TKIs.\n\n5. **Clinical Monitoring**: Regular monitoring of blood counts and the percentage of blasts is essential during this phase to ensure that the disease remains stable and to detect any progression to the accelerated or blast phases.\n\nOverall, the chronic phase of CML is marked by a slower progression of the disease, manageable symptoms, and effective treatment options, making it a critical period for patient management and intervention.
subject: Medicine
file_name: what-characterizes-the-chronic-phase-of-cml.md
url: /learn/medicine/questions/what-characterizes-the-chronic-phase-of-cml
score: -1.0
related_article1:
    id: 2277
    title: >-
        What are the most commonly used tyrosine kinase inhibitors for CML?
    subject: Medicine
    url: /learn/medicine/questions/what-are-the-most-commonly-used-tyrosine-kinase-inhibitors-for-cml
related_article2:
    id: 2274
    title: >-
        What recent advances have been made in the treatment of CML?
    subject: Medicine
    url: /learn/medicine/questions/what-recent-advances-have-been-made-in-the-treatment-of-cml
---

&nbsp;